Back

Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolaemia

28 August 2016 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster session 2 - Cardiovascular prevention outcomes I Primary cardiovascular prevention: interventions and outcomes ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor G Kees Hovingh

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

19 More presentations in this session

Presentation thumbnail
Doctor D. Huber (Uppsala, SE)
Abstract Slides
Presentation thumbnail
Doctor T. Sharma (Baltimore, US)
Abstract Slides
Presentation thumbnail
Doctor C. Badu-Boateng (Reading, GB)
Abstract Slides
Presentation thumbnail
Ms C. Barboza (Sao Paulo, BR)
Abstract Slides
Presentation thumbnail
Doctor D. Brie (Timisoara, RO)
Abstract

Access the full session

Session thumbnail
Poster session 2 - Cardiovascular prevention outcomes I

The Event

Event poster

ESC Congress 2016

28 August 2016 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Carotid plaques stabilization and regression with evolocumab
1 September 2025
thumbnail
Congress Session
Multi-disciplinary approaches to lipid management
24 June 2023
thumbnail
Congress Presentation
High long-term persistence to evolocumab treatment regimens in European clinical practice: analysis of the HEYMANS registry
27 August 2022
thumbnail
Congress Presentation
Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources